Arcus Biosciences (RCUS) Tops Q3 EPS by 2c

Arcus Biosciences (NYSE: RCUS) reported Q3 EPS of ($1.00), $0.02 better than the analyst estimate of ($1.02). Revenue for the quarter came in at $48 million versus the consensus estimate of $38.95 million.

For earnings history and earnings-related data on Arcus Biosciences (RCUS) click here.

You May Also Be Interested In

• JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
• BMO Capital on FedEx (FDX): 'Guidance Appears Consistent With Our Forecasts'
• NXP Semiconductors names Mike Lucarelli as new investor relations head